Paroxysmal Nocturnal Hemoglobinuria (PNH): Soliris Infusion Therapy
PNH is a rare blood disorder that can cause serious complications if untreated. Soliris was the first therapy to directly address its underlying cause.
What is PNH?
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired blood disorder in which red blood cells are missing certain protective proteins, leaving them vulnerable to destruction by part of the immune system (the complement system). This can cause anemia, fatigue, dark urine, abdominal pain, and a significantly increased risk of dangerous blood clots.
PNH is diagnosed through specialized blood testing (flow cytometry) that identifies the abnormal red blood cells, and severity varies widely between patients.
How infusion therapy helps
Soliris (eculizumab) was the first treatment approved specifically for PNH, working by blocking the complement system component responsible for destroying red blood cells, addressing the disease at its immune root.
Treatment significantly reduces the need for blood transfusions in most patients and, importantly, lowers the risk of blood clots, which is one of the most serious complications of untreated PNH. Dosing starts weekly before moving to a maintenance schedule every two weeks.
Diagnosed with PNH?
Our physician-led team coordinates Soliris infusion therapy closely with your hematologist.
Call (551) 336-5580This article is for general educational purposes and is not a substitute for medical advice. Treatment decisions should always be made with your physician based on your individual diagnosis and health history.